| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
13,870,000 |
| Market
Cap: |
583.93(M) |
| Last
Volume: |
2,897,500 |
Avg
Vol: |
64,821 |
| 52
Week Range: |
$17.67 - $38.49 |
|
| Level
I Sector: |
Basic Materials |
| Level
II Sector: |
Chemicals |
| Level
III Sector: |
Specialty Chemicals |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Surmodics is a provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Co.'s segments are: Medical Device, which develops and manufactures vascular intervention medical device products and is engaged in Co.'s proprietary surface modification coating technologies that impart lubricity, pro-healing, biocompatibility characteristics, or drug-delivery capabilities to medical devices and delivery systems; and IVD, which manufactures and sells components for IVD immunoassay and molecular tests within the diagnostic, biomedical research, and life science markets.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
9,872 |
| Total Sell Value |
$0 |
$0 |
$0 |
$335,339 |
| Total People Sold |
0 |
0 |
0 |
3 |
| Total Sell Transactions |
0 |
0 |
0 |
3 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barclay Bruce |
President & CEO |
• • – |
2009-11-15 |
4 |
D |
$23.38 |
$191,132 |
D/D |
(8,175) |
82,255 |
|
- |
|
| Lopez Paul A |
VP, President - Ophthamology |
• – – |
2009-11-09 |
4 |
S |
$23.87 |
$599,500 |
D/D |
(25,000) |
9,445 |
|
- |
|
| Ankeny Philip D |
Senior VP & CFO |
• – – |
2009-10-06 |
4 |
AS |
$29.75 |
$148,750 |
D/D |
(5,000) |
32,228 |
|
- |
|
| Lopez Paul A |
VP, President - Ophtalmology |
• – – |
2009-07-25 |
4 |
D |
$24.90 |
$17,804 |
D/D |
(715) |
34,445 |
|
- |
|
| Olson Charles W |
VP & Gen Mgr - Cardiovascular |
• – – |
2009-05-19 |
4 |
S |
$20.31 |
$182,384 |
D/D |
(8,980) |
19,242 |
|
- |
|
| Robey Brian L |
VP of Product Devlpmt & Ops |
• – – |
2009-05-15 |
4 |
D |
$19.65 |
$12,733 |
D/D |
(648) |
2,000 |
|
- |
|
| Olson Charles W |
VP & Gen Mgr - Cardiovascular |
• – – |
2009-03-21 |
4 |
D |
$18.03 |
$17,525 |
D/D |
(972) |
28,222 |
|
- |
|
| Duran Lise W |
VP of Research |
• – – |
2009-03-21 |
4 |
D |
$18.03 |
$11,683 |
D/D |
(648) |
59,017 |
|
- |
|
| Astry Douglas P |
Gen Mgr, In Vitro Technologies |
• – – |
2009-03-21 |
4 |
D |
$18.03 |
$5,842 |
D/D |
(324) |
6,217 |
|
- |
|
| Anderson Aron B |
VP & Chief Scientific Officer |
• – – |
2009-03-21 |
4 |
D |
$18.03 |
$11,683 |
D/D |
(648) |
38,187 |
|
- |
|
| Lopez Paul A |
VP & President - Ophtalmology |
• – – |
2009-02-27 |
4 |
S |
$17.80 |
$53,400 |
D/D |
(3,000) |
35,160 |
|
- |
|
| Lopez Paul A |
VP & President - Ophtalmology |
• – – |
2009-02-26 |
4 |
S |
$17.97 |
$53,910 |
D/D |
(3,000) |
38,160 |
|
- |
|
| Duran Lise W |
VP of Research |
• – – |
2009-02-25 |
4 |
S |
$18.04 |
$36,072 |
D/D |
(2,000) |
58,477 |
|
- |
|
| Keller Kenneth H |
Director |
– • – |
2009-02-12 |
4 |
OE |
$6.56 |
$39,375 |
D/D |
6,000 |
24,700 |
|
- |
|
| Buhrmaster Robert C |
Director |
– • – |
2009-02-10 |
4 |
B |
$19.09 |
$50,111 |
D/D |
2,625 |
2,625 |
2.39 |
- |
|
| Knight Susan E |
Director |
– • – |
2009-02-09 |
4 |
B |
$18.97 |
$9,486 |
D/D |
500 |
500 |
2.39 |
- |
|
| Barclay Bruce |
President & CEO |
• • – |
2008-12-01 |
4 |
D |
$20.78 |
$101,926 |
D/D |
(4,905) |
88,798 |
|
- |
|
| Astry Douglas P |
Gen Mgr, In Vitro Technologies |
• – – |
2008-11-28 |
4 |
S |
$22.34 |
$13,407 |
D/D |
(600) |
6,541 |
|
- |
|
| Webster Jan M |
VP of HR |
• – – |
2008-11-17 |
4 |
D |
$24.25 |
$17,969 |
D/D |
(741) |
7,649 |
|
- |
|
| Webster Jan M |
VP of HR |
• – – |
2008-11-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,268 |
8,390 |
|
- |
|
| Tipton Arthur J |
Vice President |
• – – |
2008-11-17 |
4 |
D |
$24.25 |
$63,923 |
D/D |
(2,636) |
18,798 |
|
- |
|
| Tipton Arthur J |
Vice President |
• – – |
2008-11-17 |
4 |
A |
$0.00 |
$0 |
D/D |
3,618 |
21,434 |
|
- |
|
| Shoup Michael J |
VP of Qual, Reg & Clinical |
• – – |
2008-11-17 |
4 |
D |
$24.25 |
$17,969 |
D/D |
(741) |
5,814 |
|
- |
|
| Shoup Michael J |
VP of Qual, Reg & Clinical |
• – – |
2008-11-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,268 |
6,555 |
|
- |
|
| Robey Brian L |
VP & Gen Mgr Drug Delivery |
• – – |
2008-11-17 |
4 |
D |
$24.25 |
$20,225 |
D/D |
(834) |
5,384 |
|
- |
|
888 Records found
|
|
Page 28 of 36 |
|
|
